Published in Lancet on January 24, 2012
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Prevention and early detection of prostate cancer. Lancet Oncol (2014) 2.94
Prostate cancer screening and the management of clinically localized disease. BMJ (2013) 2.45
The Study of Active Monitoring in Sweden (SAMS): a randomized study comparing two different follow-up schedules for active surveillance of low-risk prostate cancer. Scand J Urol (2013) 2.29
What (if anything) to do about low-risk prostate cancer. Lancet (2012) 1.47
Secondary chemoprevention of localized prostate cancer by short-term androgen deprivation to select indolent tumors suitable for active surveillance: a prospective pilot phase II study. World J Urol (2013) 1.42
Active surveillance for the management of localized prostate cancer: Guideline recommendations. Can Urol Assoc J (2015) 1.38
Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov (2013) 1.18
Utility of 5-alpha-reductase inhibitors in active surveillance for favourable risk prostate cancer. Can Urol Assoc J (2014) 0.92
Differential expression of 5-alpha reductase isozymes in the prostate and its clinical implications. Asian J Androl (2014) 0.90
5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med (2014) 0.85
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine (2016) 0.82
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. Int J Biol Sci (2016) 0.81
Doubly blind: a systematic review of gender in randomised controlled trials. Glob Health Action (2016) 0.80
Current status of 5α-reductase inhibitors in prostate disease management. Korean J Urol (2013) 0.80
Active surveillance for low-risk prostate cancer. F1000 Med Rep (2012) 0.80
Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. PLoS One (2015) 0.80
5α-Reductase inhibition coupled with short off cycles increases survival in the LNCaP xenograft prostate tumor model on intermittent androgen deprivation therapy. J Urol (2014) 0.80
Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. J Urol (2012) 0.79
Validation of the omega-3 fatty acid intake measured by a web-based food frequency questionnaire against omega-3 fatty acids in red blood cells in men with prostate cancer. Eur J Clin Nutr (2015) 0.77
A tale of two trials: The impact of 5α-reductase inhibition on prostate cancer (Review). Oncol Lett (2014) 0.76
Urological cancer: Are we redeemed from aggressive treatment for prostate cancer? Nat Rev Clin Oncol (2012) 0.75
Grade-dependent Response to Finasteride in Early Prostate Cancer. EBioMedicine (2016) 0.75
5-ARI use in active surveillance: Different paradigm than primary prevention but caution still needed. Can Urol Assoc J (2014) 0.75
Hormonal therapy in metastatic prostate cancer: current perspectives and controversies. Oncol Rev (2013) 0.75
Prostate cancer: Dutasteride--a welcome addition to active surveillance? Nat Rev Urol (2012) 0.75
Penile Rehabilitation Strategies Among Prostate Cancer Survivors. Rev Urol (2015) 0.75
Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial. Res Rep Urol (2014) 0.75
[Prostate cancer - Progression slowed in low-risk tumors]. Aktuelle Urol (2013) 0.75
Words of wisdom. Re: dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Eur Urol (2013) 0.75
The intriguing role of fibroblasts and c-Jun in the chemopreventive and therapeutic effect of finasteride on xenograft models of prostate cancer. Asian J Androl (2015) 0.75
The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses. Can Urol Assoc J (2013) 0.75
Words of wisdom: Re: Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Eur Urol (2012) 0.75
Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial. World J Urol (2016) 0.75
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. Eur Urol (2017) 0.75
The influence of finasteride on the development of prostate cancer. N Engl J Med (2003) 24.45
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Effect of dutasteride on the risk of prostate cancer. N Engl J Med (2010) 12.78
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2011) 11.02
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Long-term survival of participants in the prostate cancer prevention trial. N Engl J Med (2013) 7.53
Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA (2006) 7.20
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA (2005) 6.50
CBP/p300-mediated acetylation of histone H3 on lysine 56. Nature (2009) 4.83
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet (2006) 4.49
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila) (2008) 3.99
Molecular characterization of human prostate carcinoma cell lines. Prostate (2003) 3.81
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst (2006) 3.62
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol (2009) 3.31
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest (2002) 2.65
Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study. J Urol (2013) 2.65
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem (2005) 2.05
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol (2007) 1.97
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. J Clin Oncol (2007) 1.95
B7-h4 is highly expressed in ductal and lobular breast cancer. Clin Cancer Res (2005) 1.94
Comprehensive quality-of-life outcomes in the setting of a multidisciplinary, equal access prostate cancer clinic. Urology (2010) 1.85
Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int (2011) 1.84
Chemoprevention of prostate cancer. J Urol (2009) 1.70
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am J Pathol (2010) 1.65
Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. Cancer Epidemiol Biomarkers Prev (2012) 1.63
A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia. Eur Urol (2012) 1.61
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61
The MAPP research network: design, patient characterization and operations. BMC Urol (2014) 1.56
Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res (2003) 1.55
Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study. BJU Int (2011) 1.54
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol (2005) 1.54
Tolerability of 5 mg solifenacin once daily versus 5 mg oxybutynin immediate release 3 times daily: results of the VECTOR trial. J Urol (2010) 1.51
B7-H4 overexpression in ovarian tumors. Gynecol Oncol (2005) 1.51
The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy. J Urol (2008) 1.49
The cost of treating the 10 most prevalent diseases in men 50 years of age or older. Am J Manag Care (2006) 1.47
The MAPP research network: a novel study of urologic chronic pelvic pain syndromes. BMC Urol (2014) 1.47
Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial. Urology (2009) 1.45
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study. J Urol (2011) 1.44
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. Eur Urol (2007) 1.44
Protection from Alzheimer's-like disease in the mouse by genetic ablation of inducible nitric oxide synthase. J Exp Med (2005) 1.40
Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy. BJU Int (2005) 1.32
Clinical-pathologic correlation between transperineal mapping biopsies of the prostate and three-dimensional reconstruction of prostatectomy specimens. Prostate (2012) 1.18
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience. Cancer Prev Res (Phila) (2010) 1.17
Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int (2005) 1.17
Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Support Care Cancer (2013) 1.12
The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol (2006) 1.12
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. J Urol (2008) 1.11
Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome. Am J Clin Pathol (2011) 1.11
A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int (2008) 1.10
Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther (2008) 1.10
Acute tubular necrosis is characterized by activation of the alternative pathway of complement. Kidney Int (2005) 1.10
An assessment of the diagnosed prevalence of diseases in men 50 years of age or older. Am J Manag Care (2006) 1.08
Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol (2007) 1.08
Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. Cancer Epidemiol Biomarkers Prev (2009) 1.07
Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology (2011) 1.06
Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res (2013) 1.06
Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol (2012) 1.03
Stage migration and grade inflation in prostate cancer: Will Rogers meets Garrison Keillor. J Natl Cancer Inst (2005) 1.02
2-Methoxyestradiol inhibits prostate tumor development in transgenic adenocarcinoma of mouse prostate: role of tumor necrosis factor-alpha-stimulated gene 6. Clin Cancer Res (2006) 1.02
Calorie restriction modulates renal expression of sterol regulatory element binding proteins, lipid accumulation, and age-related renal disease. J Am Soc Nephrol (2005) 1.01
Optimization of prostate cancer diagnosis by increasing the number of core biopsies based on gland volume. Int J Clin Exp Pathol (2012) 0.99
Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. Cancer Prev Res (Phila) (2010) 0.98
Current perspectives on Gleason grading of prostate cancer. Curr Urol Rep (2011) 0.97
Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol (2006) 0.97
Clear cell urothelial carcinoma of the urinary bladder: a case report and review of the literature. J Med Case Rep (2014) 0.96
Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Mol Morphol (2002) 0.94
Spectral karyotype (SKY) analysis of human prostate carcinoma cell lines. Prostate (2003) 0.94
Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials (2007) 0.94
The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate. Urology (2005) 0.93
Genome-wide association study identifies a new locus JMJD1C at 10q21 that may influence serum androgen levels in men. Hum Mol Genet (2012) 0.93
Endothelial nitric oxide synthase-deficient mice exhibit increased susceptibility to endotoxin-induced acute renal failure. Am J Physiol Renal Physiol (2004) 0.92
Caspases, Bcl-2 proteins and apoptosis in autosomal-dominant polycystic kidney disease. Kidney Int (2002) 0.92
Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila) (2013) 0.90
VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men. Clin Cancer Res (2008) 0.90
Low serum testosterone levels are poor predictors of sexual dysfunction. BJU Int (2010) 0.90
Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer. Urology (2008) 0.89
Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr Med Res Opin (2013) 0.88
Finasteride decreases the risk of prostatic intraepithelial neoplasia. J Urol (2007) 0.87
p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms. Cancer Lett (2008) 0.87
Sarcomatoid intracardiac metastasis of a testicular germ cell tumor closely resembling primary cardiac sarcoma. Hum Pathol (2003) 0.87